Salute e Benessere

Groupe Casino: Judgment granting request by FRH and Casino for exemption of…

Judgment granting request by FRH and Casino for exemption of mandatory tender offer obligation regarding Cnova as provided in Article 5:70(1) of the Dutch Financial Supervision Act Paris, 21 June 2024Casino Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR001400OKR3) hereby informs as follows: also on behalf of France Retail Holdings S.à r.l. (an entity ultimately controlled by Mr. Daniel Křetínský) (“FRH”), it is hereby announced that FRH and Casino Guichard-Perrachon S.A…
Nasdaq GlobeNewswire
21/06/2024

ISTH Releases Evidence-Based Clinical Practice Guideline for Hemophilia…

The objective of this guideline is to offer a comprehensive overview of evidence in making informed treatment decisions. Developed over several years, the ISTH assembled a multidisciplinary panel comprising physicians and patient representatives with global representation, balanced to mitigate potential biases. This diverse panel prioritized key clinical questions and outcomes crucial for both clinicians and patients. The objective of this guideline is to offer a comprehensive overview of...
PR Newswire
21/06/2024

Idorsia's novel treatment for chronic insomnia wins the prestigious Prix Galien…

Idorsia's dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien Suisse 2024 innovation prize in the category 'Primary & Speciality'.Each year, the Prix Galien Suisse honors the most innovative new medicines and diagnostics on the Swiss market.Allschwil, Switzerland – June 21, 2024Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been...
Nasdaq GlobeNewswire
21/06/2024

Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for…

ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential first- and best-in-class treatments to the rare blood disorders communityInterim results from the long-term XTEND-ed phase 3 study demonstrate once-weekly ALTUVIIIO continues to provide highly effective bleed protectionNew ATLAS phase 3 study data reinforce the potential of fitusiran to...
Nasdaq GlobeNewswire
21/06/2024

Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. OnOctober...
PR Newswire
21/06/2024

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

The article continued: Last year, the FDA granted a total of 50 approvals for various oncology drugs. This year, the National Cancer Institute projects there will be an estimated 2,001,140 new cases of cancer diagnosed in the USA in 2024, with an expected 611,720 people projected to die from the disease. The article continued: Last year, theFDAgranted atotal of 50 approvalsfor various oncology drugs. This year, theNational Cancer Instituteprojects there will be anestimated...
PR Newswire
20/06/2024

Polycystic Ovarian Syndrome Market to Advance at Moderate CAGR During the Study…

Key Takeaways from the Polycystic Ovarian Syndrome Market Report Key Takeaways from the Polycystic Ovarian Syndrome Market Report Discover which therapies are expected to grab the major polycystic ovarian syndrome market share @Polycystic Ovarian Syndrome Market Report Polycystic Ovarian Syndrome Overview Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women, presenting a variety of signs, symptoms, and phenotypes. These can include reproductive,...
PR Newswire
20/06/2024

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for…

TALE base editors are a recent and important addition to the gene editing landscape. By design, TALE base editors do not create break within DNA strands as does CRISPR/Cas9, or other engineered nucleases, and is a promising therapeutic strategy for genetic diseases. A key aspect to broaden the scope of possible applications is our comprehension of design rules.TALE base editors rely on the deamination of cytidines within double strand DNA, leading to the formation of an uracil (U)...
Nasdaq GlobeNewswire
20/06/2024

Zealand Pharma announces positive topline results from the Phase 1b 16-week…

Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintideBody weight reductions of up to a mean of 8.6% with high dose petrelintide after 16 weekly doses (1.7% with placebo)Petrelintide was judged to be safe and well tolerated at all dose levelsResults provide robust support of the potential of petrelintide as an effective alternative to...
Nasdaq GlobeNewswire
20/06/2024

Custom T-shirt Printing Market Size to Hit $12,059.5 million by 2031: Coherent…

Market Dynamics: Market Dynamics: The custom t-shirt printing market is driven by increasing popularity of customized fashion among millennial population across the globe. Custom printed t-shirts allow customers to design their own t-shirts with unique graphics, logos, and slogans according to their preferences. This has increased the demand for custom printing over the recent past. Moreover, availability of wide range of fabrics, styles, designs, and printing technologies has further...
PR Newswire
20/06/2024

Abzena and Argonaut Partner to Offer Accelerated End-to-End Drug Development…

The partnership removes the white space in drug development for biopharma drug companies by utilizing a single development and manufacturing team to seamlessly transition from early discovery services (ranging from antibody engineering, developability, formulation development, cell line development, process and analytical development) through clinical and commercial manufacturing of drug substance and drug product. This tight integration of activities facilitates more informed and rapid…
PR Newswire
20/06/2024

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its…

Rapafusyn's RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously undruggable disease targets Financing led by 3E Bioventures Capital and Proxima Ventures Ltd. with participation from Lapam Capital Founded by Professor Jun O. Liu of Johns Hopkins University School of Medicine, a pioneer in the molecular glue field BALTIMORE, June20, 2024(GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals,...
Nasdaq GlobeNewswire
20/06/2024

Minimally Invasive Surgical Instruments Market Surges to USD 49.9 Billion by…

Browse in-depth TOC on "Minimally Invasive Surgical Instruments Market" Browse in-depth TOC on "Minimally Invasive Surgical Instruments Market" 450 - Tables 54 - Figures 428 - Pages TheJune 2024edition of the minimally invasive surgical instruments market report introduces significant enhancements and updates to provide a comprehensive view of the market: These enhancements in theJune 2024edition aim to deliver deeper insights and a more comprehensive...
PR Newswire
20/06/2024

Ventilators Market to be Worth $13.23 Billion by 2031 - Exclusive Report by…

A ventilator is a medical device designed to deliver oxygen into a person's body through a tube inserted into the windpipe, typically through the mouth or nose. Before entering the body, the air passes through a humidifier and filter to ensure it is clean and comfortable to breathe. Ventilators are equipped with adjustable settings for controlling the breathing rate and the volume of air delivered to the patient. A ventilator is a medical device designed to deliver oxygen into a person's body...
PR Newswire
20/06/2024

LELO partners up with Sexy Living

"We are excited to bring true innovation to even more consumers, especially in these challenging times. For us, this means playing a crucial part in opening up the adult products category worldwide. Just like we design our products for the future, we also act for the future - thus, we need to contribute to the well-being of people, and providing pleasure plays a huge part in that. Our existing and future customers in Canada deserve nothing less" says Louise Wong, Senior Business…
PR Newswire
20/06/2024

Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing…

Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in AfricaParis, June 20, 2024.Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa. This agreement is designed to enable regional manufacturing of polio vaccines to serve the potential needs of over 40 African countries. This partnership with Sanofi makes Biovac the first African producer...
Nasdaq GlobeNewswire
20/06/2024

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX…

SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The co-primary endpoints of the cohort are objective…
PR Newswire
20/06/2024

Tilray Medical Launches Broken Coast Medical Cannabis Brand in Australia

Broken Coast EU-GMP Certified Medical Cannabis Whole Flower Products Are Now Available through a Doctor's Prescription in Australia NEW YORK and SYDNEY, June20, 2024(GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, thereby transforming healthcare…
Nasdaq GlobeNewswire
20/06/2024

Roborock Secures Spot in Kantar BrandZ Top 50 Chinese Global Brand Builders for…

BrandZ Award: A Mark of Excellence BrandZ Award: A Mark of Excellence Kantar BrandZ, a globally recognized authority on brand equity, leverages the expansive consumer insights from its Kantar Profiles network. In partnership with Google, the eighth annual Chinese Global Brand Builders Report employs a stringent research methodology, integrating Kantar's extensive database with Google's detailed consumer surveys and search analytics to evaluate over 400 Chinese brands, ultimately...
PR Newswire
20/06/2024

ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of…

With a significant track record of success in the radiopharmaceutical industry, Dr. Cavey will help accelerate ITM's pipeline and business growth Garching / Munich, Germany, June 20, 2024 –ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company today announced the appointment of Dr. Andrew Cavey, as its Chief Executive Officer effective September 1, 2024. ITM's current CEO, Steffen Schuster, will step up to the company's Supervisory Board...
Nasdaq GlobeNewswire
20/06/2024

Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary…

CM313 is a humanized monoclonal antibody targeting CD38 and the first domestically-developed anti-CD38 antibody with IND approval by the NMPA in China. Previous phase I/II studies have demonstrated the favorable safety profile and encouraging efficacy of CM313 in patients with RRMM and primary ITP. In addition, the potential use of CM313 in SLE is currently under clinical development. CM313 is a humanized monoclonal antibody targeting CD38 and the first domestically-developed anti-CD38…
PR Newswire
20/06/2024

iOnctura announces EUR80 million Series B financing to progress pipeline through…

Lead asset roginolisib is the first allosteric modulator of PI3Kδ, with a unique chemical structure and binding mode. It is being developed for indications burdened by immune mediated resistance and a high expression of PI3Kδ in cancer cells and tumor-infiltrating immune cells. Roginolisib has potential to become the first successful, clinically meaningful therapy to target the critical PI3Kδ cancer pathway. It has demonstrated an unprecedented and first-in-class clinical profile in solid and…
PR Newswire
20/06/2024

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform…

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disordersat the FOCIS Annual Meeting, San Francisco (June 18 – 21)NANTES, France, June 20, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), presented a poster on preclinical data on its mRNA (messenger RiboNucleic Acid) therapeutic platform for the treatment of inflammatory and autoimmune disorders at the Federation of...
Nasdaq GlobeNewswire
20/06/2024

Basilea partners oncology drug candidate lisavanbulin with Glioblastoma…

Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with the Glioblastoma Foundation Inc., for Basilea's oncology drug candidate lisavanbulin (BAL101553), which has been developed as a potential therapy for glioblastoma, the most common type of primary brain...
Nasdaq GlobeNewswire
20/06/2024
Altri  Comunicati